Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss
March 28, 2019 4:14 PM EDTBiocept (NASDAQ: BIOC) reported Q4 EPS of ($1.43), $0.15 better than the analyst estimate of ($1.58). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $930 thousand.
"Revenues and billable samples for the fourth quarter reached their highest levels in 2018, as we benefited from our refocused commercial strategy," said Michael Nall, President and CEO of Biocept. "Our efforts to enhance our growth in test volumes has continued into 2019.
"A key driver of growth is the relaunch of our... More
